Polyrizon Ltd.
PLRZHealthcare|Biotechnology|IL
$11.04
-0.55 (-4.70%)
DCF Value
$0.81
Tangible Book / Share
$12.17
Cash / Share
$8.31
Financials
Financial Snapshot
Market Cap
$12.4M
Enterprise Value
$4.0M
Revenue (TTM)
$0.00
Net Income (TTM)
-$5.5M
Cash & Investments
$15.0M
Net Cash
$15.0M
Free Cash Flow (TTM)
-$7.0M
Operating CF (TTM)
-$7.0M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$15.0M
Quarterly Burn
$1.7M
Monthly Burn
$582.8K
Est. Runway
~8.6 quarters
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $10.0K | $523.0K | $36.0K | $41.0K | $2.6M | $12.3M | $15.0M | |
| Operating Cash Flow | -$73.0K | -$492.0K | -$1.1M | -$537.0K | -$1.1M | -$4.5M | -$7.0M | |
| Free Cash Flow | -$79.0K | -$511.0K | -$1.1M | -$537.0K | -$1.1M | -$4.5M | -$7.0M | |
| Capital Expenditure | -$6.0K | -$19.0K | -$3.0K | $0.00 | $0.00 | -$7.0K | -$12.0K | |
| Financing Cash Flow | $89.0K | $1.0M | $648.0K | $505.0K | $3.7M | $19.8M | $11.8M |
R&D Spending
R&D (TTM)
$4.1M
R&D Intensity
—
R&D Growth vs Prior
+92.6%
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $38.0K | $245.0K | $347.0K | $332.0K | $534.0K | $2.1M | $4.1M | |
| SG&A | $33.0K | $452.0K | $548.0K | $303.0K | $768.0K | $3.8M | $7.7M |
Income Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $1.0K | $6.0K | $5.0K | $4.0K | $118.0K | $342.0K | $306.0K | |
| Gross Profit | -$1.0K | -$6.0K | -$5.0K | -$4.0K | -$118.0K | -$342.0K | -$306.0K | |
| R&D | $38.0K | $245.0K | $347.0K | $332.0K | $534.0K | $2.1M | $4.1M | |
| SG&A | $33.0K | $452.0K | $548.0K | $303.0K | $768.0K | $3.8M | $7.7M | |
| Operating Income | -$72.0K | -$703.0K | -$895.0K | -$635.0K | -$1.3M | -$6.2M | -$12.7M | |
| Interest Expense | $0.00 | $2.0K | $2.0K | $2.0K | $3.0K | $3.1M | $7.0K | |
| Pretax Income | -$73.0K | -$711.0K | -$779.0K | -$600.0K | -$1.5M | -$3.3M | -$5.5M | |
| Net Income | -$73.0K | -$711.0K | -$779.0K | -$600.0K | -$1.5M | -$3.3M | -$5.5M | |
| EPS (Diluted) | 0.00 | 0.00 | 0.00 | 0.00 | -134.14 | -2.07 | -4.55 | |
| EBITDA | -$72.0K | -$703.0K | -$772.0K | -$631.0K | -$1.4M | -$5.9M | -$12.3M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 1.61 | 1.81 |
Balance Sheet
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.0K | $523.0K | $36.0K | $4.0K | $2.6M | $1.3M | $8.4M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $37.0K | $0.00 | $11.0M | $6.6M | |
| Total Current Assets | $19.0K | $544.0K | $51.0K | $54.0K | $2.7M | $12.9M | $16.3M | |
| Total Assets | $24.0K | $687.0K | $546.0K | $559.0K | $5.5M | $21.4M | $24.9M | |
| Total Current Liabilities | $8.0K | $690.0K | $1.2M | $502.0K | $261.0K | $443.0K | $448.0K | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $8.0K | $690.0K | $1.2M | $750.0K | $261.0K | $443.0K | $448.0K | |
| Stockholders' Equity | $16.0K | -$3.0K | -$652.0K | $57.0K | $5.3M | $21.0M | $24.4M | |
| Retained Earnings | -$1.4M | -$2.1M | -$2.9M | -$3.5M | -$5.1M | -$8.4M | -$9.8M |
Cash Flow Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$73.0K | -$492.0K | -$1.1M | -$537.0K | -$1.1M | -$4.5M | -$7.0M | |
| Capital Expenditure | -$6.0K | -$19.0K | -$3.0K | $0.00 | $0.00 | -$7.0K | -$12.0K | |
| Free Cash Flow | -$79.0K | -$511.0K | -$1.1M | -$537.0K | -$1.1M | -$4.5M | -$7.0M | |
| Investing Cash Flow | -$6.0K | -$19.0K | -$3.0K | $0.00 | $29.0K | -$16.5M | -$15.9M | |
| Financing Cash Flow | $89.0K | $1.0M | $648.0K | $505.0K | $3.7M | $19.8M | $11.8M | |
| Issuance of Stock | $89.0K | $1.0M | $648.0K | $256.0K | $3.7M | $19.8M | $7.8M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $648.0K | $249.0K | -$6.0K | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $184.0K | $130.0K | $100.0K | $51.0K | $0.00 | $1.3M | |
| Net Change in Cash | $10.0K | $513.0K | -$487.0K | -$32.0K | $2.5M | -$1.2M | -$7.4M |
Dilution Tracker
Shares outstanding grew 57414.1% over 5 years — significant dilution
Shares Outstanding
1M
5-Year Share Growth
+57414.1%
Stock Issuance (TTM)
$7.8M
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 1.61 | 1.81 | |
| Change vs Prior % | — | — | — | — | 327.9% | 13341.4% | 12.5% | |
| Stock Issuance | $89.0K | $1.0M | $648.0K | $256.0K | $3.7M | $19.8M | $7.8M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $184.0K | $130.0K | $100.0K | $51.0K | $0.00 | $1.3M |
Margins & Profitability
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| ROE % | -456.3% | 23700.0% | 119.5% | -1052.6% | -29.2% | -15.9% | -24.1% | |
| ROA % | -304.2% | -103.5% | -142.7% | -107.3% | -27.9% | -15.6% | -22.0% | |
| ROIC % | -450.0% | 23433.3% | 137.3% | -247.1% | -24.6% | -29.8% | -52.2% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | -500.0% | 16.7% | 20.0% | -2850.0% | -189.8% | |
| Operating Income | 0.0% | -876.4% | -27.3% | 29.1% | -105.0% | -380.0% | |
| Net Income | 0.0% | -874.0% | -9.6% | 23.0% | -157.5% | -115.9% | |
| EPS (Diluted) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 98.5% | |
| Operating Cash Flow | 0.0% | -574.0% | -130.1% | 52.6% | -113.6% | -294.8% | |
| Free Cash Flow | 0.0% | -546.8% | -122.1% | 52.7% | -113.6% | -295.4% | |
| R&D Expense | 0.0% | 544.7% | 41.6% | -4.3% | 60.8% | 299.4% | |
| SG&A Expense | 0.0% | 1269.7% | 21.2% | -44.7% | 153.5% | 391.4% | |
| Total Assets | 0.0% | 2762.5% | -20.5% | 2.4% | 892.3% | 286.5% | |
| Book Value / Share | 0.0% | 0.0% | 0.0% | 0.0% | 803.5% | -97.3% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 0.0% | 327.9% | 13341.4% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.82
10Y Low / Med / High0.65 / 6.77 / 114.06
EV/EBITDAAt Loss
10Y Low / Med / High0.05 / 0.14 / 0.74
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.81
Tangible Book / Share
$12.17
Net Current Assets / Share
$14.15
Graham Net-Net
$8.07
Cash / Share
$8.31
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| P/E Ratio | 0.00 | 0.00 | 0.00 | -10.84 | -24.27 | -4.10 | -2.43 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 0.00 | 0.00 | 0.00 | 114.06 | 6.77 | 0.65 | 0.82 | |
| EV/EBITDA | 0.14 | 0.74 | 0.05 | -10.61 | -23.35 | -2.09 | -0.32 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
15.09
Safe
Piotroski F-Score
0
Weak